GlassScriptPhysician profile
Abdalla A Tahiri
NPI 1558330431
$447.24
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $302 · 2020: $38.62 · 2021: $106.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $172.82 | 2019-2021 | |
| Indivior INC. | $84.95 | 2019 | |
| Allergan, INC. | $82.53 | 2019 | |
| Evoke Pharma, INC. | $34.67 | 2020-2021 | |
| Braintree Laboratories, INC. | $28.90 | 2019 | |
| Medtronic, INC. | $26.31 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $17.06 | 2021 |
1 company reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdalla Tahiri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.